Omalizumab is generally well tolerated in adults and children with allergic asthma. Adverse events most commonly observed are injection-site reaction, viral infection, upper-respiratory-tract ...
The following is a summary of “CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study,” published in the ...
Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.
The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...
Novartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but the company says it has gone one better with new ...
An unnamed 22-year-old man in Israel suffered from an extremely rare condition that caused him to be allergic to his own orgasms, according to a report in the American Journal of Case Reports.
Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...
Prompt injection is the highest profile vulnerability in AI-powered features and applications. It's also one of the most misunderstood. The impact varies greatly depending on who will use the feature, ...
Table 1 Antibody-mediated and genetic depletion models for the in vivo study of basophils in different pathological conditions. The authors also evaluated the cytokines produced in the heart 3 days ...
io.net partners with Injective (INJ)to enhance decentralized AI and blockchain projects, providing scalable GPU resources for developers. This collaboration aims to democratize AI access and stimulate ...
The current price of Injective (INJ) is $13.67, as of February 8, 2025. Over the last 24 hours, the price has moved by -3.32%, with a change of 0.1% in the past hour. For longer-term performance, the ...